Abstract: A solid electrolytic capacitor (1) includes an anode foil (2a) having formed thereon an oxide film, a cathode foil (2c), and a separator (2d), and is equipped with a solid electrolyte (20) formed of an electroconductive polymer compound in a fine particle form, and a water-soluble compound solution (30) introduced to surround the solid electrolyte (20), the solid electrolyte (20) contains a polyol compound having a molecular weight of less than 200 and a number of hydroxy groups of 4 or more as a first water-soluble compound (2f1), the water-soluble compound solution (30) contains one kind or multiple kinds of a glycol compound in a liquid form as a second water-soluble compound (2f2), and the second water-soluble compound (2f2) has an average molecular weight of less than 400.

Abstract: A printing apparatus includes a carriage mounted with a printing unit; a first motor configured to move the carriage in a predetermined direction; a second motor configured to move the carriage in the predetermined direction; and a control unit. The control unit executes a first mode in which, when causing the printing unit to perform printing under a first printing condition, the first motor is driven in a first direction and the second motor is driven in the first direction, and a second mode in which, when causing the printing unit to perform printing under a second printing condition different from the first printing condition, the first motor is driven in the first direction and the second motor is driven in the first direction while changing an output ratio between the first motor and the second motor.

Abstract: A pharmaceutical composition for external use, including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) N-methyl-2-pyrrolidone.

Abstract: A transmission system includes: a first transmission apparatus to distribute a synchronization clock; and one or more second transmission apparatuses each to connect to the first transmission apparatus so as to synchronize with the synchronization clock from the first transmission apparatus, the second transmission apparatus including: a selection portion to select the first or second transmission apparatus of a connection destination so as to switch the synchronization clock; an output portion to generate an inquiry signal addressed to the first transmission apparatus via the second transmission apparatus of the connection destination selected; a determination portion to determine whether or not the inquiry signal generated by the second transmission apparatus is received; and a second control portion to determine that there is a synchronization clock loop having a loop path through the second transmission apparatus of the connection destination when the determination portion receives the inquiry signal.

Abstract: A transmission system includes: a first transmission apparatus to distribute a synchronization clock; and one or more second transmission apparatuses each to connect to the first transmission apparatus so as to synchronize with the synchronization clock from the first transmission apparatus, the second transmission apparatus including: a selection portion to select the first or second transmission apparatus of a connection destination so as to switch the synchronization clock; an output portion to generate an inquiry signal addressed to the first transmission apparatus via the second transmission apparatus of the connection destination selected; a determination portion to determine whether or not the inquiry signal generated by the second transmission apparatus is received; and a second control portion to determine that there is a synchronization clock loop having a loop path through the second transmission apparatus of the connection destination when the determination portion receives the inquiry signal.

Abstract: An object of the present invention is to provide a medicinal composition useful for external application in the treatment of a fungal infection reaching the lower part of a thick keratin layer. Provided is an antifungal medicinal composition, comprising: (1) a film-forming agent; (2) a water-soluble plasticizer in a form of a solid or a paste at 20° C. at 1 atm; and (3) an antifungal compound represented by a general formula (1) and/or a physiologically acceptable salt thereof.

Abstract: A pharmaceutical composition for external use, including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) one or two or more selected from N-methyl-2-pyrrolidone, propylene carbonate, and crotamiton.

Abstract: Provided is a pharmaceutical composition for external use, including: (i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and (ii) ?-hydroxycarboxylic acid and/or a salt thereof.

Abstract: Provided is a pharmaceutical composition for external use, including: (i) a compound represented by structural formula (2) and/or a salt thereof; and (ii) N-methyl-2-pyrrolidone.

Abstract: An object of the present invention is to provide a medicinal composition useful for external application in the treatment of a fungal infection reaching the lower part of a thick keratin layer. Provided is an antifungal medicinal composition, comprising: (1) a film-forming agent; (2) a water-soluble plasticizer in a form of a solid or a paste at 20° C. at 1 atm; and (3) an antifungal compound represented by a general formula (1) and/or a physiologically acceptable salt thereof.

Abstract: Provided is a pharmaceutical composition for external use which includes the following components: 1) luliconazole and/or a salt thereof; 2) N-methyl-2-pyrollidone; and 3) benzyl alcohol and/or diester of a dibasic acid. The diester of the dibasic acid is a diethyl ester or a diisopropyl ester of a dibasic acid having 6-10 carbon atoms. The pharmaceutical composition is useful for the treatment of a mycotic disease such as foot trichophytosis, trichophytosis corporis, trichophytosis on a hard keratin or hyperkeratotic portion, onychomycosis, particularly on a nail, or dermatomycosis.

Abstract: An object of the present invention is to provide a medicinal composition useful for external application in the treatment of a fungal infection reaching the lower part of a thick keratin layer. Provided is an antifungal medicinal composition, comprising: (1) a film-forming agent; (2) a water-soluble plasticizer in a form of a solid or a paste at 20° C. at 1 atm; and (3) an antifungal compound represented by a general formula (1) and/or a physiologically acceptable salt thereof.

Abstract: The present invention provides genes and proteins having possibilities to generate plants having tolerance against excessive boron, which can confer a boric acid tolerance to organisms. 5 types of genes that can confer a boric acid tolerance to yeast, such as AtPAB2, AtRBP47c?, AtRPS20B, AtMYB13 and AtMYB68, AtRBP45a, AtRBP45b, AtRBP45c, AtRBP45d, AtRBP47a, AtRBP47b, AtRBP47c, AtUBP1a, AtUBP1b and AtUBP1c which were found by expressing several genes of higher plant Arabidopsis thaliana in yeast that is a organism model of eukaryote. Further, a key to the toxicity mechanism of boric acid exists in the specific inhibition of splicing, and a gene related to enhancement of splicing efficiency also confers a boric acid tolerance.

Abstract: A transmission apparatus that does not include a plurality of switches, that cross-connects a signal, and that can handle various redundancy settings determined by a user. An address information generation section generates address information indicative of the destination of a signal, from redundancy setting information and cross connect setting information. An activation information setting section activates and deactivates activation information included in the address information when failure occurs. An address information insertion section inserts the address information stored in an address information storage section into the signal and outputs the signal to a bus. A signal output section receives the signal having the address information that is the same as own address information and outputs the signal to a next stage in the case of the activation information indicating activation.

Abstract: A pharmaceutical composition for external use, including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) one or two or more selected from N-methyl-2-pyrrolidone, propylene carbonate, and crotamiton.

Abstract: Provided is a pharmaceutical composition for external use, including: (i) a compound represented by the general structural formula (1) and/or a salt thereof; and (ii) N-methyl-2-pyrolidone: Where, X represents a hydrogen atom or a chlorine atom.

Abstract: Provided is a pharmaceutical composition for external use, including: (i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and (ii) ?-hydroxycarboxylic acid and/or a salt thereof.

Abstract: A transmission apparatus that does not include a plurality of switches, that cross-connects a signal, and that can handle various redundancy settings determined by a user. An address information generation section generates address information indicative of the destination of a signal, from redundancy setting information and cross connect setting information. An activation information setting section activates and deactivates activation information included in the address information when failure occurs. An address information insertion section inserts the address information stored in an address information storage section into the signal and outputs the signal to a bus. A signal output section receives the signal having the address information that is the same as own address information and outputs the signal to a next stage in the case of the activation information indicating activation.

Abstract: The present invention provides genes and proteins having possibilities to generate plants having tolerance against excessive boron, which can confer a boric acid tolerance to organisms. 5 types of genes that can confer a boric acid tolerance to yeast, such as AtPAB2, AtRBP47c?, AtRPS20B, AtMYB13 and AtMYB68, AtRBP45a, AtRBP45b, AtRBP45c, AtRBP45d, AtRBP47a, AtRBP47b, AtRBP47c, AtUBP1a, AtUBP1b and AtUBP1c which were found by expressing several genes of higher plant Arabidopsis thaliana in yeast that is a organism model of eukaryote. Further, a key to the toxicity mechanism of boric acid exists in the specific inhibition of splicing, and a gene related to enhancement of splicing efficiency also confers a boric acid tolerance.

Abstract: A correct viable cell number of a microorganism in a biological tissue is measured by cultivating a fragment of the biological tissue such as skin infected with the microorganism and administered with an antimicrobial agent, in a medium containing a phospholipid, a nonionic surfactant, or both of the phospholipid and the nonionic surfactant.